{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:46:10Z","timestamp":1761918370529},"reference-count":27,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":84,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2001,9,27]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Combined medical treatment may provide further benefit to primary biliary cirrhosis (PBC) patients administered ursodeoxycholic acid (UDCA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>To evaluate the long\u2010term effects of colchicine and UDCA in symptomatic PBC patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients\/methods:<\/jats:title><jats:p>We extended up to 10\u2003years the double\u2010blind treatment of 44 symptomatic PBC patients originally included in a 3\u2010year multicentre study comparing UDCA and colchicine (U\u2003+\u2003C) versus UDCA and placebo (U\u2003+\u2003P). Outcome measures were death or liver transplantation; incidence of clinically relevant events; clinical and quantitative variables retaining prognostic information.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Mean follow\u2010up was 7\u2003\u00b1\u20033\u2003years. One patient was lost, three withdrew because of jaundice (U\u2003+\u2003P); two patients stopped colchicine but remained on UDCA. Eleven patients (two for liver\u2010unrelated reasons, U\u2003+\u2003P) and six patients (U\u2003+\u2003C) died, three and two patients, respectively, were transplanted (incidence rate difference, five cases per 100 patient\u2010years; 95% CI, \u22121 to 11). Hepatocellular carcinoma developed in one (U\u2003+\u2003P) and four (U\u2003+\u2003C) patients (difference, \u22122; CI, \u22125 to 1), portal hypertension complications in nine patients from each group (difference, 1; CI, \u22125 to 6). Trends of serum bilirubin, Mayo score, antipyrine clearance were similar among treatment groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>In cirrhotic PBC patients, colchicine does not offer additional benefits to UDCA. In this population, UDCA does not obviate disease progression.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2001.01018.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:45:08Z","timestamp":1047354308000},"page":"1427-1434","source":"Crossref","is-referenced-by-count":36,"title":["Ten\u2010year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double\u2010blind, placebo\u2010controlled trial on symptomatic patients"],"prefix":"10.1111","volume":"15","author":[{"given":"P. M.","family":"Battezzati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Zuin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Crosignani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Allocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Selmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Villa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Podda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/he.2000.5984"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)11293-X"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)72401-6"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199611213352107"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00869.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198806303182602"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198612043152304"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(87)80053-3"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(88)90300-9"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840110208"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1991.tb00035.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)91974-5"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840220311"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840140607"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)90696-7"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(96)80191-7"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510240520"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00432479"},{"key":"e_1_2_5_20_2","first-page":"401","article-title":"Spectrophotometric assay of antipyrine in plasma: a reevaluation","volume":"17","author":"Greenblatt DJ","year":"1979","journal-title":"Int J Clin Pharmacol Biopharm"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840100102"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.300.6719.230"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(05)80214-4"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1995.tb00380.x"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1992.tb00980.x"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260508"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01536665"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199630050-00002"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01018.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01018.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2001.01018.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T15:25:09Z","timestamp":1695828309000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2001.01018.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9,27]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2001,9,27]]}},"alternative-id":["10.1046\/j.1365-2036.2001.01018.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2001.01018.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,9,27]]}}}